International Lung Cancer Congress | Conference

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Understanding the Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer

July 29th 2021

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29th 2021

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

July 27th 2020

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Chiang on Unanswered Questions With Immunotherapy in NSCLC

July 27th 2020

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Lara Shares Updates With Immunotherapy in Extensive-Stage SCLC

July 27th 2020

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

Osimertinib Results Show Potential for Earlier TKI Use in EGFR-Mutant NSCLC

July 27th 2020

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

Gandara Reflects on Current Status of TMB in NSCLC

July 27th 2020

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma

July 24th 2020

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

July 24th 2020

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Aggarwal Lends Insight on the Use of TKIs and Liquid Biopsies in ALK+ NSCLC

July 24th 2020

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

Bunn Breaks Down the Latest With Antibody-Drug Conjugates in Lung Cancer

July 24th 2020

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

TRK Inhibitors Are a Safe, Effective Option in TRK Fusion-Positive Cancers

July 24th 2020

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

Moving Toward Newfound Diagnostic, Treatment Paradigms in Lung Cancer

July 23rd 2020

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

New Tools Support Translational Strides in NSCLC

July 23rd 2020

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

Adjuvant Osimertinib Possesses Potential to Revolutionize NSCLC Treatment, But Longer Follow-Up Needed

July 23rd 2020

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

July 23rd 2020

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Gandara on the Utility of TMB in NSCLC

July 23rd 2020

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Dr. Bazhenova on New Developments in RET-Rearranged NSCLC

July 28th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

Dr. Wakelee on Advances in EGFR-Mutant NSCLC Treatment

July 28th 2019

Heather A. Wakelee, MD, professor of medicine (oncology), Stanford University Medical Center, discusses osimertinib and its role in treating patients with EGFR-mutant non–small cell lung cancer.